London (RNS) inside information
Date: 18.05.2020 07:00 - Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
Date: 23.12.2019 07:01 - ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
Date: 19.12.2018 07:00 - GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture
Date: 03.12.2018 12:02 - GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
Date: 30.10.2018 14:30 - ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen
Date: 14.06.2018 07:00 - ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
Date: 27.03.2018 06:00 - GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
Date: 23.10.2017 07:00 - Shingrix approved in the US for prevention of shingles in adults aged 50 and over
Date: 20.09.2016 07:00 - GSK appoints new CEO
Date: 19.12.2016 22:01 - ViiV announce phase III results for 2-drug regimen
Other key information
-
London (RNS)
All London Stock Exchange required announcements
-
New York (SEC)
All New York Stock Exchange announcements and filings
-
Quarterly results
Discover our latest financial performance announcement and search for historical quarterly results materials
-
Press releases
Keep up to date with our news and recent announcements
